Obicitrapid currently undergoing phase 3 trials. An oral, once daily CEPT inhibitor, that can be used in combination with high intensity statins +/- ezetimibe to reduce LDL-C
Biologics in dyslipidaemia. Trials underway targeting lowering Lp(a) and Apo-CIII. 2026 for CV outcomes data for inclisiran. Watch this space! #ESCCongress
Incredibly impressed with @MjBPharm for all the expectional work he's put into SDEC. Bringing a piece of that to #CPCongress Plenty of interest and questions. @IamNat@LeedsHospitals @LeedsMedicines @